The effects of ketanserin on ventricular ectopic activity in humans

Marks, Christine; Dews, Ian; Gould, Susan; Stephens, John D.; Vandenburg, M. J.

doi:10.1007/bf00053436

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with ketanserin alone had no arrhythmogenic effect, in agreement with the findings of a larger study [9]. In another study using patients with cardiovascular disease and at least 15 ectopic beats/hour [10], ketanserin was found to reduce significantly the number of ectopics and improved the overall score for rhythm disturbance. These observations are in contrast with the reported adverse interaction of ketanserin with potassium-losing diuretics, resulting in ventricular arrhythmias [11].…”

Section: Resultssupporting

confidence: 77%

A placebo-controlled crossover study of ketanserin in elderly hypertensive patients

McCarthy¹,

McCarthy²,

John³

et al. 1990

Cardiovasc Drug Ther

Self Cite

View full text Add to dashboard Cite

The results of the European Working Party for Hypertension in the Elderly Study showed that treatment of high blood pressure reduced the morbidity and mortality from strokes and myocardial infarction and reduced the incidence of heart failure in elderly patients. The largest number of hypertensive patients are elderly, and it is in this group of patients that the maximum benefit of treatment might be expected. The present study was designed to study in detail the efficacy and tolerability of ketanserin in an elderly population. Seventeen elderly (greater than 70 years) patients with a lying systolic blood pressure of 160 mmHg and/or a diastolic blood pressure of greater than or equal to 90 mmHg were included in the study. For the 12 patients who completed the study, the mean blood pressure was significantly reduced on ketanserin compared with placebo (p less than 0.001) in the supine and erect positions. The mean net changes in blood pressure after 8 weeks were 21/17 mmHg and 23/16 mmHg erect. Heart rate was also significantly reduced (p less than 0.001) by a mean of 8 beats/min lying and 9 beats/min erect. Analysis of ambulatory 24-hour ECG tapes showed no significant effect of ketanserin on heart rhythms. Ketanserin therapy had no significant effect on routine hematology, plasma electrolytes, biochemistry, or urinalysis. Total exchangeable sodium and potassium and body weight were also unchanged. On ketanserin treatment, the overall quality of life score was significantly improved (p = 0.002; analysis of variance on log transformed data) compared with the placebo phase.

show abstract

Section: Resultssupporting

confidence: 77%

A placebo-controlled crossover study of ketanserin in elderly hypertensive patients

McCarthy¹,

McCarthy²,

John³

et al. 1990

Cardiovasc Drug Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Ketanserin

Brogden¹,

Sorkin²

1990

Drugs

View full text Add to dashboard Cite

Ketanserin is a 5-HT2 receptor antagonist without partial agonist properties which also possesses weak alpha 1-adrenoceptor antagonistic activity, which may explain its antihypertensive mechanism of action in patients with essential hypertension. It also inhibits the effects of serotonin on platelets in cardiovascular disease, inhibits vasoconstriction caused by the amine, and when administered intravenously improves some haemorheological indices in patients with ischaemic diseases. The antihypertensive effect of oral ketanserin 40 mg twice daily is comparable with that of total daily doses of metoprolol 200 mg, propranolol 160 mg, captopril 100 mg, enalapril 20 mg, hydrochlorothiazide 50 mg, or alpha-methyldopa 1000 mg and is achieved without adverse effect on plasma lipoproteins or carbohydrate metabolism in patients with concomitant diabetes mellitus. Evidence from prospective studies suggests a greater antihypertensive efficacy in the elderly than in younger patients. In patients with intermittent claudication, results have been inconsistent in small studies, while a large study showed no improvement in pain-free walking distance but fewer amputations compared to placebo. In Raynaud's phenomenon symptomatic improvement relative to placebo was achieved in larger trials. Its role in preventing atherosclerotic complications requires further investigation. Ketanserin is reasonably well tolerated, the frequency of adverse effects being comparable with that of other antihypertensive drugs in controlled trials. Dizziness, tiredness, oedema, dry mouth and weight gain are the most commonly reported effects. Ketanserin prolongs QT interval in a dose-related manner, and when given in certain predisposing circumstances ventricular arrhythmias and syncope may occur. Administered intravenously, ketanserin 10mg followed by an infusion of 2 to 4 mg/h controls moderate to severe pre- and postoperative hypertension in most patients, acting as a balanced vasodilator, lowering cardiac pre- and afterload. Although the arrhythmogenic potential of ketanserin in patients receiving potassium-depleting diuretics requires suitable precautions, it appears that its antihypertensive activity is suited to the elderly provided plasma potassium concentrations are normal at the start of treatment and are maintained within the normal range.

show abstract

The effects of ketanserin on ventricular ectopic activity in humans

Cited by 2 publications

References 8 publications

A placebo-controlled crossover study of ketanserin in elderly hypertensive patients

A placebo-controlled crossover study of ketanserin in elderly hypertensive patients

Ketanserin

Contact Info

Product

Resources

About